Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1 Kimiidera,, Wakayama, 641-8510, Japan.
Br J Surg. 2014 Aug;101(9):1084-91. doi: 10.1002/bjs.9544. Epub 2014 Jun 26.
Pancreaticoduodenectomy (PD) is associated with a high incidence of postoperative complications including pancreatic fistula. This randomized clinical trial compared the incidence of pancreatic fistula between the isolated Roux-en-Y (IsoRY) and conventional reconstruction (CR) methods.
Patients admitted for PD between June 2009 and September 2012 in a single centre were assigned randomly to CR or IsoRY. The primary endpoint was the incidence of pancreatic fistula (grade A-C) defined according to the International Study Group on Pancreatic Fistula. Secondary endpoints were complication rates, mortality and hospital stay. Multiple logistic regression analysis was performed to identify factors associated with pancreatic fistula.
Some 153 patients were randomized, 76 to CR and 77 to IsoRY; two patients from the IsoRY group were excluded after randomization. Pancreatic fistula occurred in 26 patients (34 per cent) in the CR group and 25 (33 per cent) in the IsoRY group (P = 0·909). The number of patients with a clinically relevant pancreatic fistula (grade B or C) was similar in the two groups (10 and 11 patients respectively; P = 0·789), as were complication rates (42 versus 40 per cent; P = 0·793) and mortality (none in either group; P = 0·999). Soft pancreas was the only independent risk factor for pancreatic fistula (odds ratio 4·42, 95 per cent confidence interval 1·85 to 10·53; P <0·001).
This study showed that IsoRY reconstruction does not reduce the incidence of pancreatic fistula compared with CR.
NCT00915863 (http://www.clinicaltrials.gov/) and UMIN000001967 (http://www.umin.ac.jp/).
胰十二指肠切除术(PD)术后并发症发生率较高,包括胰瘘。本随机临床试验比较了孤立 Roux-en-Y(IsoRY)与常规重建(CR)方法术后胰瘘的发生率。
2009 年 6 月至 2012 年 9 月期间,在单中心收治的 PD 患者被随机分配至 CR 或 IsoRY 组。主要终点是根据国际胰腺瘘研究组定义的胰瘘(A级-C 级)发生率。次要终点是并发症发生率、死亡率和住院时间。采用多因素逻辑回归分析确定与胰瘘相关的因素。
共有 153 例患者被随机分组,CR 组 76 例,IsoRY 组 77 例;随机分组后有 2 例 IsoRY 组患者被排除。CR 组中 26 例(34%)和 IsoRY 组中 25 例(33%)患者发生胰瘘(P=0.909)。两组中均有 10 例和 11 例患者发生临床相关胰瘘(B 级或 C 级)(P=0.789),并发症发生率(42%比 40%,P=0.793)和死亡率(均为 0%,P=0.999)也相似。软胰腺是胰瘘的唯一独立危险因素(比值比 4.42,95%置信区间 1.85 至 10.53;P<0.001)。
本研究表明,与 CR 相比,IsoRY 重建并不能降低胰瘘的发生率。
NCT00915863(http://www.clinicaltrials.gov/)和 UMIN000001967(http://www.umin.ac.jp/)。